Multiple neuroinflammation-related targets

Multiple neuroinflammation-related targets represent a heterogeneous group of molecular entities that mediate the inflammatory response within the central nervous system (CNS). This category includes pro-inflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1 beta (IL-1 beta), enzymes like Cyclooxygenase-2 (COX-2), and specialized markers of glial activation such as the Translocator Protein (TSPO) (DiSabato et al., 2016, J. Neurochem. [1]). These targets play a critical role in the pathogenesis of neurodegenerative diseases, including Alzheimer's and Parkinson's, where chronic microglial activation leads to sustained release of neurotoxic factors and subsequent neuronal loss (Tansey et al., 2022, Nat. Rev. Immunol. [2]). Drugs interacting with these targets, such as monoclonal antibodies or small molecule inhibitors, aim to dampen the neuroinflammatory cascade to preserve cognitive and motor functions (Heneka et al., 2018, Nat. Rev. Immunol. [3]). For instance, anti-TNF therapies and NLRP3 inflammasome inhibitors are being investigated for their ability to reduce neuroinflammation-driven pathology. However, because this term encompasses a wide array of distinct proteins rather than a single specific molecule, it is classified as a therapeutic category rather than a canonical drug target. Effective therapeutic intervention often requires high specificity to avoid systemic side effects while ensuring sufficient penetration of the blood-brain barrier (Guilarte, 2019, Pharmacol. Ther. [4]). Monitoring these targets often involves imaging techniques like PET or measuring fluid biomarkers like GFAP and NfL to assess the extent of CNS inflammation.

Other names

Neuroinflammatory targetsNeuroinflammation-associated proteinsCNS inflammatory mediatorsNeuroinflammatory cascade components

Inhibition of pro-inflammatory cytokine signaling, modulation of microglial and astrocytic activation states, antagonism of specific inflammatory receptors, and suppression of intracellular inflammasome assembly.